Novo Nordisk’s Buyback Machine and Wegovy Pill Momentum Set the Stage for a Binary FDA Verdict
Published on 07/28/2026 at 03:12 | Redaktion boerse-global.de
Novo Nordisk’s stock edged higher on Monday, closing at €43.76, as investors digested a flurry of corporate activity that included a multi-billion-dollar share buyback, an expanding patient base for its oral Wegovy pill, and a fresh legal offensive against arch-rival Eli Lilly. Yet the Danish drugmaker remains 26.5% below its July 2025 record high of €59.56, a gap that underscores the market’s fixation on a single regulatory question: will CagriSema clear the FDA later this year?
The combination therapy, which pairs GLP-1 with amylin, is widely seen as Novo’s best shot at reclaiming its competitive edge in the obesity market. The company submitted its approval application in December 2025, and a decision is expected in the fourth quarter of 2026. No official PDUFA date has been confirmed by either the FDA or Novo, leaving traders to price in a wide range of outcomes. The stock’s annualized 30-day volatility of nearly 27% suggests the market remains deeply uncertain about which scenario will materialize.
Buybacks and Pill Sales Provide a Floor
While the CagriSema narrative dominates the long-term outlook, Novo’s near-term fundamentals have received a noticeable boost. Between July 20 and July 24, 2026, the company repurchased roughly 960,000 of its own B-shares, bringing the total under its current buyback program to nearly 26 million shares. The program, launched in February 2026 with a total authorization of 15 billion Danish kroner, has now spent approximately 7.16 billion kroner at an average price of 276.33 kroner per share. Novo currently holds treasury stock equivalent to 1% of its total share capital, and the buyback is scheduled to run through February 2027.
At the same time, the oral Wegovy pill is proving to be a meaningful growth driver. Since its U.S. launch on January 5, 2026, more than 3 million prescriptions have been written, with over 80% of those coming from patients who had never previously used a GLP-1 therapy. That suggests the pill is expanding the market rather than cannibalizing existing injectable products like Ozempic or Wegovy. The European Commission granted approval for the tablet on July 15, paving the way for a broader international rollout in the second half of the year. Novo’s stock rose 3% on that news alone.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
A Legal Salvo Against Lilly
The positive momentum from buybacks and pill sales unfolded against a backdrop of intensifying legal tensions. On July 21, Novo Nordisk filed a lawsuit against Eli Lilly in a federal court in New Jersey, accusing the U.S. rival of running misleading television advertisements for Zepbound and Mounjaro. The complaint alleges that Lilly’s ads compare its products to outdated, lower-dose versions of Wegovy while ignoring the higher-dose 7.2-mg Wegovy HD formulation, which received FDA approval in March 2026. A hearing on a potential preliminary injunction against the Lilly ads is scheduled for August 17.
The Bull Case: Pipeline Depth and a Discounted Valuation
Optimists point to several factors that could support a recovery even before the FDA decision lands. Beyond CagriSema, Novo’s pipeline includes additional amylin candidates and potential label expansions, according to new CEO Maziar Doustdar. At the ADA scientific sessions in 2026, CagriSema demonstrated a 1.91% reduction in HbA1c compared to standard therapies — data that bolsters the drug’s profile ahead of the regulatory review.
Valuation also offers a potential cushion. Novo’s stock currently trades at roughly 11.8 times earnings, well below the European pharmaceutical sector average of about 21 times. That discount could indicate that much of the bad news — including the competitive threat from Lilly and the patent cliff ahead — is already priced in. Citi recently raised its price target to 330 Danish kroner, though it maintained a “Neutral” rating.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Bear Case: A Weakened Competitive Position
The risks, however, are substantial. In the pivotal REDEFINE-4 trial, CagriSema failed to demonstrate non-inferiority to Eli Lilly’s tirzepatide on weight loss. That result complicates the commercial narrative, as payers and physicians will now weigh CagriSema against a more effective, already-established competitor. Novo itself issued a notably subdued revenue and profit forecast for 2026, citing pricing pressure in the obesity market, upcoming patent expirations, and intensifying competition. Zacks’ quantitative model currently rates the stock a “Strong Sell,” reflecting downward earnings revisions — though that metric should not be confused with the average analyst rating. The unresolved legal dispute with Lilly over advertising practices adds another layer of uncertainty, even if it is unlikely to have a near-term earnings impact.
What’s Next: Earnings and the FDA Clock
Novo Nordisk is scheduled to report first-half results on August 5, 2026. Investors will be watching for updated guidance on the Wegovy rollout and any fresh details on CagriSema’s clinical development. For now, the stock sits about 8% above its 50-day moving average of €40.48, suggesting that near-term sentiment has stabilized. But with the FDA decision still months away and the competitive landscape shifting rapidly, the next major catalyst remains binary: a green light for CagriSema could restore Novo’s growth narrative, while a delay or restrictive label would likely reinforce the view that the company has lost its innovation lead to Lilly.
Ad
Novo Nordisk Stock: New Analysis - 28 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
